| Literature DB >> 36129893 |
Julie Aarestrup1, Kim Blond1, Dorte Vistisen2,3, Marit E Jørgensen2,4,5, Marie Frimodt-Møller2, Britt W Jensen1, Jennifer L Baker1.
Abstract
BACKGROUND: Although excess adult adiposity is a strong risk factor for chronic kidney disease (CKD), evidence for associations with early life body size is limited. We investigated whether childhood body mass index (BMI) trajectories are associated with adult-onset CKD and end-stage kidney disease (ESKD) using a population-based cohort. Further, we examined the role of adult-onset type 2 diabetes (T2D) in these associations. METHODS ANDEntities:
Mesh:
Year: 2022 PMID: 36129893 PMCID: PMC9491561 DOI: 10.1371/journal.pmed.1004098
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.613
Characteristics of individuals in the CSHRR by childhood BMI trajectory and by sex.
| BMI trajectory | |||||||
|---|---|---|---|---|---|---|---|
| Sex | Characteristic | All (n) | Below-average | Average | Above-average | Overweight | Obese |
| Men | n (%) | 151,506 | 34,945 (23.1) | 64,548 (42.6) | 37,721 (24.9) | 11,854 (7.8) | 2,438 (1.6) |
| Year of birth, median (IQR) | 151,506 | 1950 (1941–1963) | 1948 (1940–1962) | 1949 (1941–1963) | 1954 (1944–1970) | 1965 (1950–1980) | |
| BMI at age 7 years, median (IQR) | 142,561 | 14.3 (13.9–14.7) | 15.3 (14.9–15.7) | 16.2 (15.7–16.7) | 17.2 (16.5–17.9) | 19.1 (18.0–20.3) | |
| BMI at age 10 years, median (IQR) | 137,454 | 15.0 (14.5–15.3) | 16.2 (15.8–16.6) | 17.6 (17.1–18.1) | 19.6 (18.9–20.4) | 22.7 (21.7–24.1) | |
| BMI at age 13 years, median (IQR) | 132,157 | 16.0 (15.4–16.4) | 17.5 (17.0–18.1) | 19.4 (18.9–20.1) | 22.0 (21.2–23.0) | 25.8 (24.7–27.3) | |
| CKD, n (%) | 5,968 (3.9) | 1,198 (3.4) | 2,554 (4.0) | 1,583 (4.2) | 539 (4.5) | 94 (3.9) | |
| ESKD, n (%) | 977 (0.6) | 198 (0.6) | 431 (0.7) | 253 (0.7) | 79 (0.7) | 16 (0.7) | |
| T2D, n (%) | 18,004 (11.9) | 3,606 (10.3) | 7,226 (11.2) | 4,787 (12.7) | 1,945 (16.4) | 440 (18.0) | |
| Death, n (%) | 38,241 (25.2) | 8,755 (25.1) | 17,082 (26.5) | 9,585 (25.4) | 2,431 (20.5) | 388 (15.9) | |
| Women | n (%) | 148,590 | 31,027 (20.9) | 59,224 (39.9) | 39,823 (26.8) | 15,057 (10.1) | 3,459 (2.3) |
| Year of birth, median (IQR) | 148,590 | 1950 (1942–1963) | 1948 (1940–1962) | 1949 (1940–1962) | 1952 (1943–1967) | 1960 (1947–1977) | |
| BMI at age 7 years, median (IQR) | 139,670 | 14.0 (13.6–14.5) | 15.0 (14.6–15.5) | 16.0 (15.4–16.6) | 17.2 (16.5–18.0) | 19.1 (18.1–20.3) | |
| BMI at age 10 years, median (IQR) | 135,381 | 14.7 (14.2–15.1) | 16.0 (15.6–16.5) | 17.5 (17.0–18.2) | 19.6 (18.8–20.4) | 22.5 (21.5–23.7) | |
| BMI at age 13 years, median (IQR) | 131,377 | 16.0 (15.4–16.5) | 17.8 (17.3–18.4) | 19.9 (19.2–20.6) | 22.4 (21.6–23.3) | 26.1 (24.9–27.5) | |
| CKD, n (%) | 3,903 (2.6) | 662 (2.1) | 1,467 (2.5) | 1,195 (3.0) | 452 (3.0) | 127 (3.7) | |
| ESKD, n (%) | 543 (0.4) | 74 (0.2) | 202 (0.3) | 169 (0.4) | 76 (0.5) | 22 (0.6) | |
| T2D, n (%) | 12,427 (8.4) | 2,022 (6.5) | 4,318 (7.3) | 3,603 (9.0) | 1,875 (12.5) | 609 (17.6) | |
| Death, n (%) | 27,816 (18.7) | 5,356 (17.3) | 11,312 (19.1) | 7,890 (19.8) | 2,752 (18.3) | 506 (14.6) | |
BMI, body mass index; CKD, chronic kidney disease; CSHRR, Copenhagen School Health Records Register; ESKD, end-stage kidney disease; IQR, interquartile range; T2D, type 2 diabetes.
*For descriptive purposes, individuals were assigned to the trajectory with the highest posterior probability.
Fig 1Childhood BMI trajectories and CKD and ESKD.
(A) CKD among men in analyses without (white) and with (black) T2D. (B) CKD among women in analyses without (white) and with (black) T2D. (C) ESKD among men in analyses without (white) and with (black) T2D. (D) ESKD among women in analyses without (white) and with (black) T2D. BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; ESKD, end-stage kidney disease; T2D, type 2 diabetes.
Cumulative incidences of CKD and ESKD by childhood BMI trajectory.
Sex-specific 10-year cumulative incidences (in percentages) of CKD and ESKD in individuals aged 55 and 65 years with and without T2D, respectively, by childhood BMI trajectories when taking competing risk of death into account.
| Men | Women | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative incidence (95% CI) | Cumulative incidence (95% CI) | |||||||||
| Disease | Age (years) | BMI trajectory | Without T2D | With T2D | Without T2D | With T2D | ||||
| CKD | 55 | Below-average | 0.73 | (0.69–0.79) | 6.46 | (5.87–7.13) | 0.51 | (0.47–0.56) | 3.89 | (3.39–4.49) |
| Average | 0.79 | (0.75–0.83) | 6.93 | (6.36–7.56) | 0.54 | (0.51–0.58) | 4.11 | (3.62–4.67) | ||
| Above-average | 0.84 | (0.79–0.90) | 7.38 | (6.73–8.04) | 0.64 | (0.59–0.68) | 4.81 | (4.24–5.43) | ||
| Overweight | 0.98 | (0.90–1.08) | 8.55 | (7.67–9.48) | 0.67 | (0.60–0.74) | 5.02 | (4.36–5.73) | ||
| Obese | 1.09 | (0.87–1.36) | 9.33 | (7.50–11.56) | 0.83 | (0.68–1.01) | 6.17 | (5.01–7.59) | ||
| 65 | Below-average | 1.79 | (1.68–1.90) | 7.91 | (7.30–8.62) | 1.07 | (0.98–1.16) | 5.36 | (4.78–6.04) | |
| Average | 1.92 | (1.84–2.01) | 8.50 | (7.91–9.12) | 1.13 | (1.07–1.20) | 5.67 | (5.13–6.27) | ||
| Above-average | 2.05 | (1.94–2.16) | 9.03 | (8.34–9.72) | 1.33 | (1.24–1.41) | 6.60 | (5.95–7.27) | ||
| Overweight | 2.39 | (2.18–2.60) | 10.41 | (9.43–11.44) | 1.38 | (1.25–1.52) | 6.82 | (6.05–7.66) | ||
| Obese | 2.62 | (2.10–3.24) | 11.17 | (9.01–13.74) | 1.71 | (1.41–2.07) | 8.32 | (6.81–10.10) | ||
| ESKD | 55 | Below-average | 0.19 | (0.16–0.22) | 0.72 | (0.56–0.95) | 0.08 | (0.06–0.11) | 0.46 | (0.31–0.69) |
| Average | 0.20 | (0.18–0.22) | 0.77 | (0.61–0.98) | 0.11 | (0.09–0.13) | 0.61 | (0.43–0.86) | ||
| Above-average | 0.20 | (0.18–0.23) | 0.78 | (0.61–0.99) | 0.13 | (0.11–0.15) | 0.71 | (0.50–0.99) | ||
| Overweight | 0.21 | (0.17–0.27) | 0.83 | (0.61–1.10) | 0.16 | (0.13–0.21) | 0.90 | (0.63–1.28) | ||
| Obese | 0.27 | (0.16–0.46) | 1.04 | (0.60–1.81) | 0.21 | (0.14–0.34) | 1.19 | (0.71–2.00) | ||
| 65 | Below-average | 0.29 | (0.25–0.34) | 0.60 | (0.47–0.77) | 0.12 | (0.09–0.15) | 0.36 | (0.25–0.53) | |
| Average | 0.31 | (0.28–0.35) | 0.64 | (0.51–0.80) | 0.16 | (0.14–0.19) | 0.48 | (0.35–0.66) | ||
| Above-average | 0.32 | (0.28–0.36) | 0.65 | (0.51–0.81) | 0.18 | (0.15–0.22) | 0.56 | (0.40–0.75) | ||
| Overweight | 0.34 | (0.27–0.42) | 0.69 | (0.51–0.91) | 0.23 | (0.18–0.30) | 0.70 | (0.50–0.98) | ||
| Obese | 0.42 | (0.25–0.72) | 0.85 | (0.48–1.48) | 0.31 | (0.19–0.49) | 0.92 | (0.55–1.54) | ||
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; ESKD, end-stage kidney disease; T2D, type 2 diabetes.
Childhood weight status and CKD and ESKD.
Sex-specific IRRs and corresponding 95% CIs of the associations between childhood weight status at ages 7, 10, and 13 years and CKD and ESKD, respectively, in analyses with and without adult-onset T2D and duration with T2D.
| All | Cases | Without T2D | With T2D | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Sex | Disease | Age (years) | Weight status | n (% | n (% | IRR | 95% CI | IRR | 95% CI |
| Men | CKD | 7 | Underweight | 6,593 (4.6) | 245 (3.7) | 1.01 | (0.88–1.14) | 0.98 | (0.87–1.12) |
| Normal weight | 126,613 (88.8) | 5,007 (4.0) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,355 (6.6) | 339 (3.6) | 1.33 | (1.19–1.49) | 1.16 | (1.04–1.30) | |||
| 10 | Underweight | 4,246 (3.1) | 152 (3.6) | 1.01 | (0.86–1.18) | 1.04 | (0.89–1.23) | ||
| Normal weight | 124,122 (90.3) | 5,168 (4.2) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,086 (6.6) | 427 (4.7) | 1.69 | (1.53–1.87) | 1.29 | (1.17–1.43) | |||
| 13 | Underweight | 7,753 (5.9) | 267 (3.4) | 0.91 | (0.80–1.03) | 0.97 | (0.86–1.10) | ||
| Normal weight | 116,466 (88.1) | 4,930 (4.2) | 1 (ref) | 1 (ref) | |||||
| Overweight | 7,938 (6.0) | 421 (5.3) | 1.92 | (1.74–2.12) | 1.37 | (1.24–1.52) | |||
| ESKD | 7 | Underweight | 6,593 (4.6) | 28 (0.4) | 0.69 | (0.47–1.01) | 0.69 | (0.47–1.00) | |
| Normal weight | 126,613 (88.8) | 829 (0.7) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,355 (6.6) | 58 (0.6) | 1.34 | (1.03–1.75) | 1.16 | (0.89–1.52) | |||
| 10 | Underweight | 4,246 (3.1) | 22 (0.5) | 0.87 | (0.57–1.33) | 0.90 | (0.59–1.38) | ||
| Normal weight | 124,122 (90.3) | 858 (0.7) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,086 (6.6) | 64 (0.7) | 1.47 | (1.14–1.90) | 1.13 | (0.87–1.46) | |||
| 13 | Underweight | 7,753 (5.9) | 43 (0.6) | 0.88 | (0.65–1.19) | 0.95 | (0.70–1.29) | ||
| Normal weight | 116,466 (88.1) | 820 (0.7) | 1 (ref) | 1 (ref) | |||||
| Overweight | 7,938 (6.0) | 64 (0.8) | 1.68 | (1.30–2.16) | 1.22 | (0.94–1.58) | |||
| Women | CKD | 7 | Underweight | 6,260 (4.5) | 154 (2.5) | 1.00 | (0.85–1.18) | 0.99 | (0.84–1.16) |
| Normal weight | 123,996 (88.8) | 3,201 (2.6) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,414 (6.7) | 262 (2.8) | 1.46 | (1.28–1.65) | 1.20 | (1.06–1.36) | |||
| 10 | Underweight | 5,107 (3.8) | 102 (2.0) | 0.85 | (0.69–1.03) | 0.87 | (0.71–1.06) | ||
| Normal weight | 121,788 (90.0) | 3,364 (2.8) | 1 (ref) | 1 (ref) | |||||
| Overweight | 8,486 (6.3) | 275 (3.2) | 1.60 | (1.41–1.81) | 1.22 | (1.07–1.38) | |||
| 13 | Underweight | 6,101 (4.6) | 126 (2.1) | 0.83 | (0.69–0.99) | 0.88 | (0.74–1.05) | ||
| Normal weight | 116,349 (88.6) | 3,237 (2.8) | 1 (ref) | 1 (ref) | |||||
| Overweight | 8,927 (6.8) | 350 (3.9) | 1.87 | (1.67–2.09) | 1.36 | (1.22–1.53) | |||
| ESKD | 7 | Underweight | 6,260 (4.5) | 15 (0.2) | 0.70 | (0.42–1.18) | 0.70 | (0.42–1.17) | |
| Normal weight | 123,996 (88.8) | 447 (0.4) | 1 (ref) | 1 (ref) | |||||
| Overweight | 9,414 (6.7) | 41 (0.4) | 1.65 | (1.19–2.27) | 1.35 | (0.98–1.87) | |||
| 10 | Underweight | 5,107 (3.8) | 12 (0.2) | 0.75 | (0.42–1.32) | 0.77 | (0.43–1.37) | ||
| Normal weight | 121,788 (90.0) | 459 (0.4) | 1 (ref) | 1 (ref) | |||||
| Overweight | 8,486 (6.3) | 50 (0.6) | 2.15 | (1.60–2.88) | 1.64 | (1.22–2.21) | |||
| 13 | Underweight | 6,101 (4.6) | 14 (0.2) | 0.68 | (0.40–1.15) | 0.72 | (0.42–1.22) | ||
| Normal weight | 116,349 (88.6) | 447 (0.4) | 1 (ref) | 1 (ref) | |||||
| Overweight | 8,927 (6.8) | 64 (0.7) | 2.46 | (1.89–3.20) | 1.83 | (1.40–2.39) | |||
CI, confidence interval; CKD, chronic kidney disease; ESKD, end-stage kidney disease; IRR, incidence rate ratio; T2D, type 2 diabetes.
*Percentage of all individuals in each weight status group.
†Percentage of cases by weight status group.